Preservatives in ophthalmology;Konservierungsmittel in der Ophthalmologie

Ophthalmologe

Volumn 109, Issue 11, 2012, Pages 1064-1070

  Messmer, E M ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Eye drops; Ocular surface disease; Ophthalmology; Preservatives; Sterility

Indexed keywords

EYE DROPS; PRESERVATIVE;

ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; EYE DISEASE; HUMAN;

ANIMALS; EYE DISEASES; HUMANS; OPHTHALMIC SOLUTIONS; PRESERVATIVES, PHARMACEUTICAL;

EID: 84870361844     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-012-2638-4     Document Type: Article

References (37)

1. Deutsches Arzneibuch. 8, 123. 1978. Deutscher Apothekerverlag, Frankfurt, Govi, Stuttgart [Ref Type: Serial (Book, Monograph)]
2. Brewitt H, Messmer EM, Geerling G (2007) Therapie des Trockenen Auges. In: Messmer EM (Hrsg) Diagnose und Therapie des Trockenen Auges. Uni-Med Verlag AG, Bremen, S 87-107
3. Baudouin C, Labbe A, Liang H et al (2010) Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res 29:312-334
4. Charnock C (2006) Are multidose over-the-counter artificial tears adequately preserved? Cornea 25:432-437
5. Champeau E, Edelhauser H (1986) Effect of ophthalmic preservatives on ocular surface: conjunctival and corneal uptake and distribution of benzalkonium chloride and chlorhexidine digluconate. In: Holly F (Hrsg) The preocular tear film. Dry Institute Inc., Lubbock
6. Friedlaender MH, Breshears D, Amoozgar B et al (2006) The dilution of benzalkonium chloride (BAK) in the tear film. Adv Ther 23:835-841
7. Conrads H, Winterhoff D, Strotmann U (1984) Pros and cons of preservatives in eyedrops. Questionnaire for practitioners and experimental studies with reference to the requirements of the German Pharmacopoeia of August 1978. Klin Monatsbl Augenheilkd 184:233-237
8. Kim MS, Choi CY, Kim JM et al (2008) Microbial contamination of multiply used preservative-free artificial tears packed in reclosable containers. Br J Ophthalmol 92:1518-1521
9. Tasli H, Cosar G (2001) Microbial contamination of eye drops. Cent Eur J Public Health 9:162-164
10. EMEA public statement on antimicrobial preservatives in ophthalmic preparations for human use. EMEA/622721/2009. 8-12-2009. London (Ref Type: Report)
11. Lewis RA, Katz GJ, Weiss MJ et al (2007) Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma 16:98-103
12. Pellinen P, Lokkila J (2009) Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost. Ophthalmic Res 41:118-122
13. Xiong C, Chen D, Liu J et al (2008) A rabbit dry eye model induced by topical medication of a preservative benzalkonium chloride. Invest Ophthalmol Vis Sci 49:1850-1856
14. Kuppens EV, Jong CA de, Stolwijk TR et al (1995) Effect of timolol with and without preservative on the basal tear turnover in glaucoma. Br J Ophthalmol 79:339-342
15. Kaercher T, Honig D, Barth W (1999) How the most common preservative affects the Meibomian lipid layer. Orbit 18:89-97
16. Hoh H (1990) Preservative-free timolol eye drops - surface-anesthetic effect and local compatibility. Ophthalmologica 200:89-97
17. Martone G, Frezzotti P, Tosi GM et al (2009) An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Am J Ophthalmol 147:725-735
18. Chandrasekaran S, Cumming RG, Rochtchina E, Mitchell P (2006) Associations between elevated intraocular pressure and glaucoma, use of glaucoma medications, and 5-year incident cataract: the Blue Mountains Eye Study. Ophthalmology 113:417-424
19. Herman DC, Gordon MO, Beiser JA et al (2006) Topical ocular hypotensive medication and lens opacification: evidence from the ocular hypertension treatment study. Am J Ophthalmol 142:800-810
20. Goto Y, Ibaraki N, Miyake K (2003) Human lens epithelial cell damage and stimulation of their secretion of chemical mediators by benzalkonium chloride rather than latanoprost and timolol. Arch Ophthalmol 121:835-839
21. Miyake K, Ibaraki N, Goto Y et al (2003) ESCRS Binkhorst lecture 2002: pseudophakic preservative maculopathy. J Cataract Refract Surg 29:1800-1810
22. Valk R van der, Webers CA, Schouten JS et al (2005) Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 112:1177-1185
23. Corazza M, Levratti A, Zampino MR, Virgili A (2002) Conventional patch tests are poor detectors of contact allergy from ophthalmic products. Contact Dermatitis 46:298-299
24. Kalavala M, Statham BN (2006) Allergic contact dermatitis from timolol and dorzolamide eye drops. Contact Dermatitis 54:345
25. Pisella PJ, Pouliquen P, Baudouin C (2002) Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 86:418-423
26. Jaenen N, Baudouin C, Pouliquen P et al (2007) Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 17:341-349
27. Jong C de, Stolwijk T, Kuppens E et al (1994) Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma. Graefes Arch Clin Exp Ophthalmol 232:221-224
28. Quigley HA, Friedman DS, Hahn SR (2007) Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data: the Glaucoma Adherence and Persistency Study. Ophthalmology 114:1599-1606
29. Schwartz GF, Quigley HA (2008) Adherence and persistence with glaucoma therapy. Surv Ophthalmol 53(Suppl1):S57-S68
30. Reardon G, Schwartz GF, Mozaffari E (2004) Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol 137:3-12
31. Schwartz GF, Reardon G, Mozaffari E (2004) Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. Am J Ophthalmol 137:S13-S16
32. Spooner JJ, Bullano MF, Ikeda LI et al (2002) Rates of discontinuation and change of glaucoma therapy in a managed care setting. Am J Manag Care 8:S262-S270
33. Baudouin C (2008) Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol 86:716-726
34. Tsai JC, McClure CA, Ramos SE et al (2003) Compliance barriers in glaucoma: a systematic classification. J Glaucoma 12:393-398
35. Nordmann JP, Auzanneau N, Ricard S, Berdeaux G (2003) Vision related quality of life and topical glaucoma treatment side effects. Health Qual Life Outcomes 1:75
36. Ammar DA, Noecker RJ, Kahook MY (2010) Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther 27:837-845
37. Noecker RJ, Herrygers LA, Anwaruddin R (2004) Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 23:490-496